Recordati Rare Diseases, Inc. Announces Transfer of U.S. Marketing Rights to SIGNIFOR® (pasireotide) Injection and SIGNIFOR LAR® (pasireotide) for Injectable Suspension 02/20/2020 Shortage of US-labeled TRANXENE T-TAB® Tablets (clorazepate dipotassium tablets, USP) 7.5 mg 02/19/2020 UPDATE to Shortage of US-labeled TRANXENE T-TAB® Tablets (clorazepate dipotassium tablets, USP) 7.5 mg 09/05/2019 Pagination First page « First Previous page ‹ Previous … Page 10 Current page 11 Page 12 Page 13 … Next page Next › Last page Last »
Recordati Rare Diseases, Inc. Announces Transfer of U.S. Marketing Rights to SIGNIFOR® (pasireotide) Injection and SIGNIFOR LAR® (pasireotide) for Injectable Suspension 02/20/2020
Shortage of US-labeled TRANXENE T-TAB® Tablets (clorazepate dipotassium tablets, USP) 7.5 mg 02/19/2020
UPDATE to Shortage of US-labeled TRANXENE T-TAB® Tablets (clorazepate dipotassium tablets, USP) 7.5 mg 09/05/2019
